Surgeon Cartu Jon Announces - Blueprint gains approval for its drug to treat a rare gastrointes... - Jonathan Cartu Family Medical Clinic & Patient Care Center
17757
post-template-default,single,single-post,postid-17757,single-format-standard,qode-quick-links-1.0,tribe-no-js,ajax_fade,page_not_loaded,,qode-theme-ver-11.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.2.1,vc_responsive

Surgeon Cartu Jon Announces – Blueprint gains approval for its drug to treat a rare gastrointes…

Blueprint gains approval for its drug to treat a rare gastrointes...

Surgeon Cartu Jon Announces – Blueprint gains approval for its drug to treat a rare gastrointes…


Blueprint Medicines won approval Thursday of its first drug, a precision medicine that dramatically shrank tumors caused by an ultra-rare form of gastrointestinal cancer.

The Food and Drug Administration’s approval of the medicine for a form of gastrointestinal stromal tumors, or GIST, marks an “incredibly exciting milestone for our company and, more importantly, for GIST patients,” said Jeff Albers, chief executive officer of the biotech based in Cambridge, Mass.

Unlock this article written by Jonathan Cartu by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED


CFOJon Cartu Medical Tourism

AiroAV Anti Malware

No Comments

Post A Comment